Ariad looks to boost Iclusig sales with two new deals
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has signed two deals for the commercialization of its leukemia drug Iclusig (ponatinib), which has had disappointing sales since its launch in the US and Europe. Ariad has signed over exclusive rights to market Iclusig in Central and Eastern Europe to Angelini Pharma – an Italian-headquartered firm, and has also entered a deal with Japanese firm Otsuka Pharmaceutical.